Icon times
Kilitch Drugs (India)

Kilitch Drugs (India)

CompanyOver

 / 
 
 

About

Highlights

Performing rate for the company

Track the companies of Group.

Relaince Group

Sector: Refineries

Market Price

2,529.50

Market Cap(₹Cr.)

2,529.50

-90.00

Quarterly Results ( Figures in Rs. Crores.)

No Data is available.

Profit & Loss ( Figures in Rs. Crores.)

No Data is available.

Balance Sheet ( Figures in Rs. Crores.)

No Data is available.

Cash Flows ( Figures in Rs. Crores.)

No Data is available.

Historical Growths

Compounded Sales Growth
Compounded Profit Growth
Compounded Expense Growth
Stock Price CAGR
No data is available
Sales Growth Profit Growth Expense Growth Stock Price CAGR

Ratios ()

No Data is available.

Major Shareholders

No Data is available.

Shareholders more than 1%

No Data is available.

Fund houses invested in the stock (Figures in % Equity Capital )

No Data is available.

Corporate Action

No Data is available.
No Data is available.
No Data is available.
No Data is available.

Documents

Presentation & Earning Calls

Annual Reports

Credit Rating

No document is available
No document is available
No document is available
No document is available.

Overview

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

Brands Of Kilitch Drugs (India)

Brands Of Kilitch Drugs (India)

undefined

Comment

Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya